COMPASS Pathways Sees Unusually Large Options Volume (NASDAQ:CMPS)

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) was the target of unusually large options trading activity on Friday. Investors purchased 7,423 call options on the company. This is an increase of approximately 152% compared to the typical daily volume of 2,940 call options.

Analyst Ratings Changes

CMPS has been the subject of a number of analyst reports. Morgan Stanley increased their target price on shares of COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Royal Bank Of Canada lifted their price objective on COMPASS Pathways from $16.00 to $21.00 and gave the stock an “outperform” rating in a research report on Friday. BTIG Research upped their target price on COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a report on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.25.

Institutional Investors Weigh In On COMPASS Pathways

Several hedge funds have recently bought and sold shares of CMPS. Advisory Services Network LLC bought a new position in shares of COMPASS Pathways during the third quarter valued at approximately $41,000. China Universal Asset Management Co. Ltd. increased its position in COMPASS Pathways by 46.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock valued at $51,000 after buying an additional 5,817 shares in the last quarter. BIT Capital GmbH purchased a new position in COMPASS Pathways during the third quarter valued at $54,000. Conservest Capital Advisors Inc. boosted its holdings in COMPASS Pathways by 32.5% in the second quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company’s stock worth $57,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Northeast Financial Consultants Inc bought a new stake in COMPASS Pathways in the second quarter worth $59,000. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Trading Up 0.6%

CMPS opened at $7.17 on Friday. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55. COMPASS Pathways has a 52 week low of $2.25 and a 52 week high of $8.20. The stock has a market cap of $688.44 million, a PE ratio of -2.64 and a beta of 1.92. The business has a 50 day moving average of $6.42 and a 200-day moving average of $5.60.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. Equities research analysts predict that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.